News

Infliximab Approved For Ulcerative Colitis


 

Infliximab (Remicade), which blocks tumor necrosis factor-α (TNF-α), is approved for maintaining clinical remission and mucosal healing in patients with moderately to severely active ulcerative colitis and who have had an inadequate response to conventional therapy. The approval is based primarily on a study that found patients on infliximab were twice as likely to be in remission at week 54, than those on placebo, according to Centocor (www.centocor.com

Recommended Reading

Natalizumab Takes Crohn's Remission Past 2 Years
MDedge Family Medicine
Hydrotherapy Excels as Safe, Tolerable Bowel Prep
MDedge Family Medicine
Alternatives to Traditional Colonoscopy Sought
MDedge Family Medicine
Eosinophilic Esophagitis Is Enigmatic in Adults
MDedge Family Medicine
Mouth Ulcers and Defects in Tooth Enamel May Suggest Celiac Disease
MDedge Family Medicine
Textbook Celiac Disease Occurs Less Often, Eluding Diagnosis
MDedge Family Medicine
Drug Combination Targets H. pylori
MDedge Family Medicine
Exercise May Help Cut Colon Cancer Risk in Men
MDedge Family Medicine
Adult Cyclic Vomiting Syndrome Is Easy to Miss
MDedge Family Medicine
What GI stress ulcer prophylaxis should we provide hospitalized patients?
MDedge Family Medicine